MGC Pharmaceuticals is launching a data collection app with a machine learning algorithm for patients and their doctors this quarter.
The ZAM app, a joint venture with developer Caba Tech, will enable patients to log their medical history and monitor medication use, wherever they are in the world.
It will also provide users with instructions on how and when to take medication, as per their healthcare practitioner’s advice, measure treatment progress, and enable a qualified doctor to prescribe alternatives following a consultation.
Once the initial phase of data collection is underway, the app’s artificial intelligence (AI) machine learning capability will use it and results from academic and clinical studies to predict potential conflicting side effects from multiple treatments.
It will also allow users to order existing prescriptions and provide their GP with data on treatment and medical history.
MGC Pharma said, in time, the statistical database created by ZAM will be useful to pharmaceutical companies, insurers and other healthcare providers, giving the company an opportunity to commercialise the app and data.
Following a closed launch phase in which data will be collected from 100 patients enrolled through the MGC Pharma’s Australian telehealth business MCC, a second phase release will be announced in Q3, 2022.
MGC Pharma co-founder and managing director Roby Zomer said: “It has been clear to us for some time that, used properly, AI has the ability to transform the pharmaceutical industry, and improve outcomes for patients.
“This app will serve as an ‘online doctor’, both collecting data and learning from it to predict conflicts in treatments, increasing efficiency for medical practitioners.
“Our conversations across the medical research industry and with patients have shown there is a real need for this app, and we truly believe that it can revolutionise the delivery of medical services for people globally.”
